DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/cj35k9/bispecific) has announced the addition of the "Concise Analysis of the International Bispecific Antibody Therapeutics Market" report to their offering.
Antibody based therapeutics are the fastest growing segment of the drugs and biologics market. There are 30 approved antibody based therapeutics available in the US and European markets since the launch of first anti-CD3 antibody, Orthoclone Okt3, in 1986.
A bispecific antibody is a second generation immunotherapy, an upgraded version of monoclonal antibody improved in structure and functionality. The conjugated artificial antibodies are formed by physically putting together two monoclonal antibodies (or parts of) which have different binding specificities. This results in a combination antibody that has simultaneous functional binding affinities to two or three different epitopes. The combination may have additive and sometimes even a synergistic effect in combating a disease.
With the EMA approval for Removab in 2009, a great deal of interest has been generated in the bispecific antibody market. The pipeline is rich and diverse, with drugs being developed for both oncological and non-oncological indications. The industry has drugs in phase I and phase II of clinical trials but currently lacks drugs in phase III.
The Bispecific Antibody Therapeutics Market, 2013-2023 report extensively studies the current and upcoming market of the bispecific antibodies for therapeutic use. This new class of antibody based therapeutics are likely to help target and combat multifactorial diseases through their potential to bind two antigens simultaneously.
Key Topics Covered:
1. EXECUTIVE SUMMARY
3. MARKET OVERVIEW AND PIPELINE OF BISPECIFIC ANTIBODIES
4. CURRENT MARKET AND FORECAST
5. TECHNOLOGY PLATFORMS
6. PROFILES OF LEADING COMPANIES
7. SWOT ANALYSIS
9. LIST OF COMPANIES AND ORGANISATIONS
- Boehringer Ingelheim
- Chiome Bioscience
- Dow Pharma
- EMD Serono
- Eli Lilly
- Epigen Biotech
- Fabion Pharmaceuticals
- Imclone Systems
- Mitsubishi Tanabe
- Molecular Partners AG
- OtSuka Pharma
- Paktis Antibody Services GmbH
- Tanabe Research Labs
- X-Body Biosciences
For more information visit http://www.researchandmarkets.com/research/cj35k9/bispecific